A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07643766
This study is recruiting at 9 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of ENV-294 in adults with moderate-to-severe atopic dermatitis (AD). The study will compare three dose levels of ENV-294 with placebo administered for 12 weeks. Participants will undergo screening, receive study treatment, and complete scheduled assessments of disease activity, symptoms, quality of life, safety, pharmacokinetics, and biomarker responses.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Atopic Dermatitis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Enveda Therapeutics
- Last updated on ClinicalTrials.gov
- August 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- Enveda Investigative Site · Encinitas, CA
- Enveda Investigative Site · Los Angeles, CA
- Enveda Investigative Site · Northridge, CA
Florida · 1
- Enveda Investigative Site · Boca Raton, FL
Indiana · 2
- Enveda Investigative Site · Indianapolis, IN
- Enveda Investigative Site · Plainfield, IN
Texas · 3
- Enveda Investigative Site · Dallas, TX
- Enveda Investigative Site · San Antonio, TX
- Enveda Investigative Site · Sugar Land, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.